Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local control of this disease. (Abstract 324)
Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)
Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostate cancer. (Plenary Lecture 1, Presentation 7)
Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.
Joanne B. Weidhaas, MD, PhD, of the University of California, Los Angeles Radiation Oncology, discusses the KRAS variant as a biomarker of cetuximab response and altered immunity in head and neck cancer. (Abstract LBA-11)
Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
